Navigation Links
Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study

Research has indicated that FlexNow(R) Joint Formula shows significant reductions in cartilage deterioration, joint inflammation, and joint pain.

EGG HARBOR TWP., N.J., Nov. 14 /PRNewswire/ -- BSP Pharma Inc., the maker and distributor of FlexNow(R) Joint Formula, has announced the findings from the new joint health clinical study completed this past June at the Australian Centre for Complementary Medicine Education and Research (ACCMER) in Brisbane, Australia led by Dr. Phillip Cheras PhD.

(Photo: )

To view the Multimedia News Release, go to:

Results show that, for those with elevated cartilage deterioration in their joints, FlexNow Joint Formula provides an unprecedented reduction in cartilage deterioration for a natural product, 44% higher than that reported for glucosamine.(1) This is the first human clinical study of a natural product showing such a great reduction in a well recognised marker for cartilage deterioration as well as significant reductions in joint specific inflammation and joint pain.

FlexNow is an all natural dietary supplement made with one ingredient, an extract from the shea nut which contains one of the most powerful inflammation fighters of any known plant. The ability of shea extract to reduce inflammation in the human body has only recently been discovered.

Dr. Cheras' was asked to be the principal investigator due to his ground breaking research showing it is highly likely that most joint problems are a vascular condition. Prior to this study, research had indicated that FlexNow had a strong ability to address this cause, and not just the symptoms of joint health.

"FlexNow shows great promise and BSP's approach to bringing this product to market is a model for responsible development for complementary medicine," said Cheras.

The research was designed to bring together a large number of previous studies, to confirm the efficacy of shea extract in humans and to further demonstrate the safety of FlexNow. FlexNow is one of only 7 dietary supplements to be accepted by the FDA in 2004 as meeting all safety requirements, which was further shown during the clinical study when there was no difference in adverse effects between FlexNow and placebo.

The biggest clinical surprise was the unprecedented reduction in the breakdown of cartilage, both compared to placebo and for that reported for glucosamine. The other remarkable findings were the strong reduction in inflammatory markers that are produced more in unhealthy joints and joint cartilage than normal joints, and high sensitivity C-reactive protein (hsCRP), which has been found to be higher in patients with unhealthy joints than controls.

"This clinical confirmation that FlexNow is significantly reducing cartilage breakdown and inflammation, gives us insight into why so many FlexNow Joint Formula users are telling us of their joint relief for the first time," said Leonard P. Smith, CEO and President, BSP Pharma Inc., "which is allowing so many people with joint pain to once again lead an active life."

The clinical study is being submitted for publication. Prior clinical studies can be found by visiting

(1) Christgau S, Henrotin Y, Tanko LB, et al. Osteoarthritic patients with

high cartilage turnover show increased responsiveness to the cartilage

protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004;


SOURCE BSP Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
Post Your Comments:
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: